Efficacy and Safety Study of Alogliptin and Insulin in the Treatment of Type 2 Diabetes.

Summary

The purpose of this study is to determine the efficacy and safety of alogliptin, once daily (QD), taken in combination with insulin for the treatment of Type 2 Diabetes.

Timeline

Start

2006-02

Primary completion

2007-05

Completion

2007-05

Outcome

Met primary endpoint

registry Placebo vs Alogliptin 25 mg QD; p <0.001; Mean Difference (Final Values) -0.59 (95% CI -0.80 to -0.37); ANCOVA NCT00286429 ↗

Publications

• Results Rosenstock J, Rendell MS, Gross JL, Fleck PR, Wilson CA, Mekki Q. Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. Diabetes Obes Metab. 2009 Dec;11(12):1145-52. doi: 10.1111/j.1463-1326.2009.01124.x. Epub 2009 Sep 16.
• Results Pratley RE, McCall T, Fleck PR, Wilson CA, Mekki Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. J Am Geriatr Soc. 2009 Nov;57(11):2011-9. doi: 10.1111/j.1532-5415.2009.02484.x. Epub 2009 Sep 30.

Drugs

Indications